v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table summarizes our segment revenue, significant segment expenses, and segment profit:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue$15,557.7 $11,302.8 $28,286.2 $20,070.8 
Less:
Cost of sales2,447.8 2,170.2 4,672.0 3,843.7 
Early-stage research and development(1)
1,156.0 1,025.3 2,146.0 1,877.4 
Late-stage research and development(1)
2,180.1 1,685.9 3,923.8 3,356.6 
Marketing, selling, and administrative2,753.0 2,117.3 5,221.8 4,069.5 
Acquired in-process research and development153.8 154.3 1,725.5 264.8 
Other segment items(2)
1,206.5 1,182.8 2,177.3 1,448.9 
Net income$5,660.5 $2,967.0 $8,419.8 $5,209.9 
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials.
(2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges.
The following tables summarize additional segment information:
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Interest expense$249.0 $183.6 $492.7 $363.2 
Interest income40.0 37.3 88.3 83.1 
Depreciation and amortization478.5 414.4 941.3 815.0 
Asset impairment, restructuring, and other special charges— 435.0 35.0 435.0 
Earnings (loss) in equity method investments
(16.0)25.9 (74.7)39.6 
Income taxes1,115.9 550.2 1,812.7 843.4 
Expenditures for long-lived assets(1)
1,985.1 1,401.3 3,501.7 2,460.9 
(1) Includes expenditures for property and equipment and computer software costs.
June 30, 2025December 31, 2024
Total assets$100,922.6 $78,714.9 
Equity method investments
1,188.4 1,142.7